(Q43861740)

27 November 2017

Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation (English)

1 reference

27 November 2017

0 references

Biagi JJ

1

1 reference

27 November 2017

Mileshkin L

2

1 reference

27 November 2017

Grigg AP

3

1 reference

27 November 2017

Westerman DW

4

1 reference

27 November 2017

Prince HM

5

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

Bone Marrow Transplantation

27 November 2017

1 reference

27 November 2017

28

1 reference

27 November 2017

12

1 reference

27 November 2017

1145-1150

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703292

27 November 2017

0 references

cites work

Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

Bone marrow angiogenesis and progression in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

Should-alpha-interferon be included as standard treatment in multiple myeloma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

Mini-allografts' for haematological malignancies: an alternative to conventional myeloablative marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

Interferon-alpha treatment of acute lymphoblastic leukemia relapse after unrelated bone marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

7 January 2021

High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

1 reference

7 January 2021

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

7 January 2021

Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

7 January 2021

Thalidomide in the treatment of relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

7 January 2021

Late and localized extramedullary relapse of a light chain kappa myeloma after syngeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

7 January 2021

Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

7 January 2021

High-dose melphalan is not associated with extramedullary relapses in high-risk multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

7 January 2021

Relapse of multiple myeloma in extramedullary sites after autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

7 January 2021

High-risk multiple myeloma treated with high-dose melphalan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

7 January 2021

Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703292

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703292

1 reference

Dimensions Publication ID

27 November 2017

0 references

1 reference